Login to Your Account

Other News To Note

Tuesday, May 17, 2011
NeuroHealing Pharmaceuticals Inc., of Newton, Mass., entered a strategic master services and investment deal with Cato BioVentures, which includes a collaboration with Cato Research Ltd., its contract research organization, to assist in the clinical development of NeuroHealing's lead drug NH001.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription